Magnus Financial Group LLC Takes $114,000 Position in Innovate Biopharmaceuticals Inc (INNT)

Magnus Financial Group LLC bought a new stake in shares of Innovate Biopharmaceuticals Inc (NASDAQ:INNT) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 49,500 shares of the company’s stock, valued at approximately $114,000. Magnus Financial Group LLC owned approximately 0.19% of Innovate Biopharmaceuticals at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. BlackRock Inc. lifted its holdings in Innovate Biopharmaceuticals by 34.1% in the 3rd quarter. BlackRock Inc. now owns 1,183,763 shares of the company’s stock worth $8,084,000 after buying an additional 301,142 shares in the last quarter. Vanguard Group Inc lifted its holdings in Innovate Biopharmaceuticals by 387.1% in the 3rd quarter. Vanguard Group Inc now owns 324,315 shares of the company’s stock worth $2,215,000 after buying an additional 257,730 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Innovate Biopharmaceuticals by 387.1% in the 3rd quarter. Vanguard Group Inc. now owns 324,315 shares of the company’s stock worth $2,215,000 after buying an additional 257,730 shares in the last quarter. Jefferies Group LLC acquired a new position in Innovate Biopharmaceuticals in the 3rd quarter worth $674,000. Finally, Bank of New York Mellon Corp lifted its holdings in Innovate Biopharmaceuticals by 71.6% in the 4th quarter. Bank of New York Mellon Corp now owns 68,676 shares of the company’s stock worth $158,000 after buying an additional 28,648 shares in the last quarter. Institutional investors and hedge funds own 12.26% of the company’s stock.

INNT opened at $2.14 on Friday. Innovate Biopharmaceuticals Inc has a 1-year low of $1.70 and a 1-year high of $50.50.

TRADEMARK VIOLATION WARNING: “Magnus Financial Group LLC Takes $114,000 Position in Innovate Biopharmaceuticals Inc (INNT)” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.wkrb13.com/2019/03/17/magnus-financial-group-llc-takes-114000-position-in-innovate-biopharmaceuticals-inc-innt.html.

Innovate Biopharmaceuticals Company Profile

Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease.

Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding INNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innovate Biopharmaceuticals Inc (NASDAQ:INNT).

Institutional Ownership by Quarter for Innovate Biopharmaceuticals (NASDAQ:INNT)

Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply